CMPS
ANALYST COVERAGE12 analysts
BUY
+55.3%upside to target
L $15.00
Med $18.00consensus
H $22.00
Buy
12100%
12 Buy (100%)0 Hold (0%)0 Sell (0%)
Full report →
Key MetricsTTM
Market Cap$1.11B
Revenue TTM$0.00
Net Income TTM-$178.95M
Free Cash Flow-$159.52M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-151.0%
Return on Assets-33.7%
Debt / Equity0.01
Current Ratio3.32
EPS TTM$-1.63
PRICE
Prev Close
10.87
Open
10.71
Day Range10.70 – 12.03
10.70
12.03
52W Range2.25 – 12.03
2.25
12.03
96% of range
VOLUME & SIZE
Avg Volume
3.9M
FUNDAMENTALS
P/E Ratio
-3.7x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.35
Market-like
TECHNICAL
RSI (14)
65
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 119 days
Sep 18

CMPS News

About

compass pathways is a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health. our first major initiative is developing psilocybin therapy through late-stage clinical trials in the eu and us for patients with treatment-resistant depression. we are developing psychoactive care pathways based on advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Guy GoodwinChief Medical Officer
Michael GoldChief Research & Development Officer
Lars Christian WildeSenior Advisor
Stephen D. SchultzSenior Vice President of Investor Relations
Anne BenedictChief People Officer
Greg RyslikChief Technology Officer
Lori EnglebertChief Commercial Officer
Teri LoxamChief Financial Officer
Steve LevineChief Patient Officer
Susan C. StansfieldAdvisor
Benjamin HarberCompany Secretary
Kabir NathChief Executive Officer & Director